The abstract is read at the publisher; the summary is JClub's.
Higher baseline plasma phosphorylated tau 217 (p-tau217) predicts greater 5- and 10-year progression from cognitive unimpaired status to MCI and dementia, with hazard ratios up to 3.99 in ADNI.
- Why it matters: Some biomarker-positive, cognitively unimpaired people remain asymptomatic, so clinicians need individualized short-term absolute risk estimates to guide prognosis and preclinical AD trial design.
- What they did: In CU adults aged 60–90 from Mayo Clinic Study of Aging (n=1644) and ADNI (n=534), continuous-time multistate models estimated transitions to MCI and dementia using baseline p-tau217 (and p-tau217/Aβ42), age, sex, and APOE ε4.
- The result: In MCSA, at age 75 with sex and APOE at cohort means, 5-year MCI risk rose from 7% (95% CI, 5%-8%) to 17% (95% CI, 13%-20%) when p-tau217 increased from 0.072 to 0.324 pg/mL, and 10-year risk rose from 15% (95% CI, 12%-18%) to 35% (95% CI, 29%-41%; P<.001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.